X
    X
    X
    X

    Edwards Wildman Closes Stemline Therapeutics IPO in First Biotech IPO of 2013

    News
    Edwards Wildman has advised Stemline Therapeutics. Inc. on its initial public offering. Trumpeted by the BioWorld headline "Stemline Therapeutics Is First Biotech IPO of 2013", the offering was well received by investors, soaring 15% on its first day of trading on the Nasdaq. The team included Ben Ferrucci on executive compensation. Ralph Loren provided counsel on intellectual property issues. Edwards Wildman has represented Stemline as general outside counsel since 2007, including with respect to several private financing and licensing matters.

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.